Journal article icon

Journal article

Identification of the first structurally validated covalent ligands of the small GTPase RAB27A

Abstract:
Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane via protein–protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket (‘WF-binding pocket’) via a conserved tryptophan–phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1039/d1md00225b
Publication website:
http://spiral.imperial.ac.uk/bitstream/10044/1/93207/7/d1md00225b.pdf

Authors

More by this author
Role:
Author
ORCID:
0009-0004-2538-6998
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-7092-8096
More by this author
Role:
Author
ORCID:
0000-0001-5987-4149
More by this author
Role:
Author
ORCID:
0000-0003-3414-8348
More by this author
Role:
Author
ORCID:
0000-0002-2370-7776


More from this funder
Funder identifier:
10.13039/100010269
Grant:
202926/Z/16/Z
More from this funder
Funder identifier:
10.13039/501100000289
Grant:
C29637/A20781
More from this funder
Funder identifier:
10.13039/501100000780
Grant:
797995
More from this funder
Funder identifier:
10.13039/501100000761
Grant:
ICiC_PS3291
More from this funder
Funder identifier:
10.13039/501100000268
Grant:
BB/D524840/1


Publisher:
Royal Society of Chemistry
Journal:
RSC Medicinal Chemistry More from this journal
Volume:
13
Issue:
2
Pages:
150-155
Publication date:
2021-12-16
DOI:
EISSN:
2632-8682
ISSN:
2632-8682


Language:
English
Keywords:
Pubs id:
1302565
Local pid:
pubs:1302565
Source identifiers:
W4200388655
Deposit date:
2026-04-29
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP